Curated News
By: NewsRamp Editorial Staff
May 19, 2026

Lantern Pharma Gains FDA Clarity for LP-300 Lung Cancer Trial

Discuss on Substack
Original Source

TLDR

  • Lantern Pharma's FDA nod for LP-300 protocol amendments targets a niche never-smoker population, potentially accelerating market approval ahead of competitors.
  • The FDA cleared Lantern Pharma's Phase 2 HARMONIC trial protocol amendments, focusing LP-300 on EGFR L858R-mutant never-smokers after TKI failure.
  • Lantern Pharma's LP-300 trial aims to improve outcomes for never-smokers with lung cancer, offering hope where current treatments fall short.
  • Lantern Pharma's AI platform RADR helped design a trial targeting a specific lung cancer mutation in never-smokers, showcasing precision oncology.

Impact - Why it Matters

This news matters because it signals a clearer regulatory pathway for LP-300, a potential new treatment for never-smokers with a specific lung cancer mutation. For patients, this could mean access to a more targeted therapy after standard treatments fail. For investors, it reduces regulatory uncertainty and highlights Lantern Pharma's progress in precision oncology. The broader implication is that AI-driven drug development, as exemplified by Lantern's RADR platform and withZeta.ai, is gaining traction, potentially accelerating the delivery of personalized cancer treatments.

Summary

Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company, has received a favorable response from the U.S. Food and Drug Administration regarding proposed protocol amendments for its ongoing Phase 2 HARMONIC™ trial. The trial evaluates LP-300, a cisplatin/ethacraplatin analog, in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The FDA’s written response to a Type C meeting request provides a clearer regulatory path, focusing on the EGFR exon 21 L858R-mutant never-smoker population. Emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure. This development is a significant milestone for Lantern Pharma as it advances its precision oncology pipeline.

Lantern Pharma leverages artificial intelligence and machine learning through its proprietary RADR® platform to transform cancer therapy development. The company’s clinical pipeline includes LP-184 (acylfulvene) and LP-284 (a TC-NER targeting compound), alongside LP-300. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned subsidiary. Additionally, Lantern has commercially launched withZeta.ai, a multi-agentic AI co-scientist platform now available as a subscription-based research platform for the global biomedical community, representing a new revenue stream. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.

The news was disseminated by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. InvestorWire provides advanced wire-grade press release syndication and enhanced distribution to a vast network of outlets, including 5,000+ syndication partners and social media reach. For the latest updates on Lantern Pharma, visit the company’s newsroom at https://ibn.fm/LTRN.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lantern Pharma Gains FDA Clarity for LP-300 Lung Cancer Trial

blockchain registration record for this content.